Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H1 2018

  • ID: 4576127
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • H. Lundbeck AS
  • NeuroDerm Ltd
  • Saniona AB
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H1 2018'; Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Neuronal acetylcholine receptor subunit beta-2 is a protein encoded by the CHRNB2 gene. Acetylcholine binds to this receptor. This results in extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H1 2018' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Nicotine Addiction, Psychiatric Disorders, Smoking Addiction, Alcohol Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Cognitive Disorders, Cognitive Impairment, Major Depressive Disorder, Neurology and Pain.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • H. Lundbeck AS
  • NeuroDerm Ltd
  • Saniona AB
  • Sopharma AD
  • Suven Life Sciences Ltd
  • MORE
Introduction

Report Coverage

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Overview

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Companies Involved in Therapeutics Development

H. Lundbeck AS

NeuroDerm Ltd

Saniona AB

Sopharma AD

Suven Life Sciences Ltd

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Drug Profiles

(nicotine + opipramol) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AP-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cytisine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-9283 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize nAChR Alpha-4 Beta-2 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNA4 and CHRNB2 for Nicotine Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SUVN-911 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

varenicline tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Dormant Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Discontinued Products

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Product Development Milestones

Featured News & Press Releases

May 07, 2018: Achieve Announces Patent Granted on Novel Formulation of Cytisine

Mar 23, 2018: Pfizer Reports Top-Line Results from a Study of CHANTIX/CHAMPIX (varenicline) in Adolescent Smokers

Feb 20, 2018: Achieve Announces Preliminary Data from Cytisine Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study

Nov 14, 2017: Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability of Cytisine in Fed and Fasted Subjects

Oct 26, 2017: Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine

Oct 04, 2017: Achieve Announces Advancement of Cytisine Clinical Development Program

Aug 16, 2017: Achieve Announces Initiation of Cytisine Clinical Development Program

Aug 10, 2017: Achieve Announces FDA Acceptance of the Investigational New Drug Application for Cytisine as a Smoking Cessation Treatment

May 25, 2017: Suven Life Sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a Neuronal Acetylcholine Nicotinic Receptor antagonist for Major Depressive Disorder

Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")

Dec 16, 2016: FDA Approves Removal Of Boxed Warning Regarding Serious Neuropsychiatric Events From CHANTIX (varenicline) Labeling

Sep 14, 2016: FDA Advisory Committees Recommend to Remove Boxed Warning in Labeling for Pfizer’s Smoking Cessation Therapy, CHANTIX (varenicline)

May 23, 2016: CHAMPIX (Varenicline) European Union Label Updated To Include New Safety And Efficacy Data From The EAGLES Clinical Trial Following Endorsement From CHMP

Apr 22, 2016: CHANTIX/CHAMPIX (Varenicline) Results From The Largest Global Clinical Trial Of Smoking Cessation Medicines Published In The Lancet

Sep 04, 2015: Quit-smoking drug safer than thought

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by H. Lundbeck AS, H1 2018

Pipeline by NeuroDerm Ltd, H1 2018

Pipeline by Saniona AB, H1 2018

Pipeline by Sopharma AD, H1 2018

Pipeline by Suven Life Sciences Ltd, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • H. Lundbeck AS
  • NeuroDerm Ltd
  • Saniona AB
  • Sopharma AD
  • Suven Life Sciences Ltd
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll